You are here: Industry Insights > clinical study

News List

Pharmaceutical News of the Week (June. 29th-July. 3rd) | PharmaSources.com - Updates on R&D PharmaSources/Caicai
July 08, 2020
Let’s review the hot events of the pharmaceutical industry this week. The news involved 5 sections: approval, R&D, policies, transactions and listing that happened during June 29-July 3, including 29 pieces.
HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study) PharmaSources
January 12, 2023
HighTide Therapeutics Inc. announced the dosing of the first patient in a Phase 2b clinical study evaluating HTD1801 for the treatment of nonalcoholic steatohepatitis ("NASH").
Results from First Clinical Study Using Danoprevir to Treat Naive and Experienced COVID-19 Patients prnasia
March 25, 2020
Ascletis Pharma Inc. (HKEX code: 1672) announces today the first clinical study using Ganovo®(danoprevir) to treat naive and experienced COVID-19 patients was published in medRxiv.
NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study prnasia
July 05, 2019
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the company has initiated the second part in its ongoing Phase Ia/b clinical study with KL1333 ...
Saluda Medical announces clinical study results of the chronic pain treatment biospectrumasia
June 03, 2019
The Evoke and Avalon studies both demonstrated improvements in pain, function, sleep, and quality of life
Imugene ‘encouraged’ by data for HER2 vaccine in gastric cancer fiercebiotech
December 26, 2018
Australian biotech Imugene says its HER2 vaccine hit the mark in a phase 1b trial, setting up a phase 2 study that will start recruiting patients in the new year.....
Visterra Initiates Phase 1 Clinical Study of VIS649 americanpharmaceuticalreview
November 10, 2018
Visterra announced the initiation of a Phase 1 clinical study with VIS649 in healthy volunteers. VIS649 is a monoclonal
Navitor Pharmaceuticals Initiates a Clinical Study of NV-5138 americanpharmaceuticalreview
June 27, 2018
Navitor Pharmaceuticals announced the initiation of a Phase 1 clinical study with its lead pipeline candidate, NV-5138, for treatment-resistant depression (TRD).
Aprea Announces First Patient Enrolled in Phase Ib/II Clinical Study of APR-246 pharmaceutical-technology
August 03, 2017
Aprea Therapeutics announced the first patient was enrolled in a Phase Ib/II clinical study of APR-246 in platinum-resistant high-grade serous ovarian cancer (HGSOC).
Bioniz Reports Top-Line Phase 1 Clinical Study Results for BNZ-1 americanpharmaceuticalreview
July 20, 2017
Bioniz Therapeutics announced top-line results from its first-in-human study of BNZ-1, a novel IL-2/IL-9/L-15 inhibitor.

Previous page 1 2 Next page